文献速递中医内科中药与中成药合理使用

代宗方通过激活PKA通路促进白色脂肪棕色化改善肥胖

The Chinese herbal medicine Dai-Zong-Fang promotes browning of white adipocytes in vivo and in vitro by activating PKA pathway to ameliorate obesity.
PubMed 文献 · Front Pharmacol · 2023-05-10

该研究在饮食诱导肥胖小鼠和3T3-L1脂肪细胞中观察代宗方的作用。体内0.40 g/kg代宗方可减轻体重、腹围和脂肪重量,降低空腹血糖和血脂,并促进腹股沟白色脂肪棕色化;体外0.8 mg/mL代宗方增加线粒体数和UCP1、PGC-1α、PKA、pCREB表达,而PKA抑制剂H-89可逆转UCP1和PGC-1α上调。结论提示代宗方通过激活PKA通路促进白色脂肪棕色化,具有抗肥胖潜力。

要点

  • 代宗方0.40 g/kg可减轻DIO小鼠肥胖并改善糖脂代谢。
  • 代宗方促进iWAT棕色化,上调UCP1、PGC-1α和PKA表达。
  • 体外PKA抑制剂H-89可逆转代宗方对UCP1和PGC-1α的上调。

核心结论

  • 代宗方通过激活PKA通路上调UCP1表达,促进白色脂肪棕色化,从而减轻肥胖及糖脂代谢异常。

研究设计与样本

  • 体内采用高脂饮食诱导的C57BL/6J肥胖小鼠模型,代宗方0.40 g/kg和0.20 g/kg、二甲双胍0.15 g/kg干预六周。
  • 体外采用成熟3T3-L1脂肪细胞,根据CCK8选择代宗方0.8 mg/mL和0.4 mg/mL干预2天,并用PKA抑制剂H-89观察棕色化标志物变化。

主要发现

  • 体内0.40 g/kg代宗方较溶剂对照组显著降低DIO小鼠体重、腹围、Lee指数和WAT/体重(p < 0.01或p < 0.001)。
  • 体内0.40 g/kg代宗方显著降低空腹血糖、血清TG、TC和LDL-C(p < 0.01或p < 0.001)。
  • 体内代宗方干预后iWAT形态和线粒体呈棕色化改变,RT-qPCR检测UCP1、PGC-1α和PKA表达升高(p < 0.05或p < 0.001)。
  • 体外0.8 mg/mL代宗方较对照组显著增加线粒体数量及UCP1、PGC-1α、PKA和pCREB表达(p < 0.05或p < 0.01)。
  • 体外加入PKA抑制剂H-89后,UCP1和PGC-1α表达被显著逆转。

临床怎么用

  • 代宗方可能作为抗肥胖候选药物,用于改善肥胖相关糖脂代谢异常。
  • 其作用机制与激活PKA通路促进白色脂肪棕色化相关,可作为后续机制研究和方药开发的参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: The global prevalence of obesity is rising rapidly. Conversion of white adipose tissue (WAT) into beige adipose tissue with heat-consuming characteristics, i.e., WAT browning, effectively inhibits obesity. Dai-Zong-Fang (DZF), a traditional Chinese medicine formula, has long been used to treat metabolic syndrome and obesity. This study aimed to explore the pharmacological mechanism of DZF against obesity. Methods: In vivo, C57BL/6J mice were fed high-fat diets to establish the diet-induced obese (DIO) model. DZF (0.40 g/kg and 0.20 g/kg) and metformin (0.15 g/kg, positive control drug) were used as intervention drugs for six weeks, respectively. The effects of DZF on body size, blood glucose and lipid level, structure and morphology of adipocytes and browning of inguinal WAT (iWAT) in DIO mice were observed. In vitro, mature 3T3-L1 adipocytes were used as the model. Concentrations of DZF (0.8 mg/mL and 0.4 mg/mL) were selected according to the Cell Counting Kit-8 (CCK8). After 2d intervention, lipid droplet morphology was observed by BODIPY493/503 staining, and mitochondria number was observed by mito-tracker Green staining. H-89 dihydrochloride, a PKA inhibitor, was used to observe the change in browning markers' expression. The expression levels of browning markers UCP1 and PGC-1α and key molecules of PKA pathway were detected in vivo and in vitro. Results: In vivo, compared with vehicle control group, 0.40 g/kg DZF significantly reduced obesity in DIO mice from body weight, abdomen circumference, Lee's index, and WAT/body weight (p < 0.01 or p < 0.001). 0.40 g/kg DZF also significantly reduced fasting blood glucose (FBG), serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) (p < 0.01 or p < 0.001). The iWAT's morphology and mitochondria were browning after DZF intervention. In HE-staining, the lipid droplets became smaller, and the number of mitochondria increased. The mitochondrial structure was remodeled under the electron microscope. The expression of UCP1, PGC-1α and PKA was elevated in iWAT detected by RT-qPCR (p < 0.05 or p < 0.001). In vitro, compared with the control group, 0.8 mg/mL DZF intervention significantly increased the number of mitochondria and expression of UCP1, PGC-1α, PKA, and pCREB (p < 0.05 or p < 0.01). In contrast, UCP1 and PGC-1α expression were significantly reversed after adding PKA inhibitor H-89 dihydrochloride. Conclusion: DZF can promote UCP1 expression by activating the PKA pathway, thereby promoting browning of WAT, attenuating obesity, and reducing obesity-related glucose and lipid metabolism abnormalities, indicating that DZF has the potential to be selected as an anti-obesity drug to benefit obese patients.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Xu J, Zhang LW, Feng H, et al. The Chinese herbal medicine Dai-Zong-Fang promotes browning of white adipocytes in vivo and in vitro by activating PKA pathway to ameliorate obesity. Front Pharmacol. 2023. PMID: 37251344. doi:10.3389/fphar.2023.1176443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。